Armata Pharmaceuticalsincis A Clinical Stage Biotechnology Company Based In Los Angelescaliforniafounded In 1989The Company Focuses On Developing Bacteriophage Based Therapeutics To Tackle Antibiotic Resistant Bacterial Infectionswith A Team Of Around 60 Professionalsarmata Is Dedicated To Creating Targeted Therapies Using Both Natural And Synthetic Phages The Company S Clinical Pipeline Includes Ap Pa02An Inhaled Phage Cocktail Designed For Chronic Pulmonary Infections Like Non Cystic Fibrosis Bronchiectasis And Cystic Fibrosisand Ap Sa02Aimed At Treating Acute Infections Such As Staphylococcus Aureus Bacteremiaarmata Emphasizes Rigorous Clinical Developmentconducting Randomized Controlled Trials To Ensure The Safety And Efficacy Of Its Therapiesthe Company Is Committed To Addressing The Global Challenge Of Antimicrobial Resistance Through Innovative Phage Therapies
